We analyzed non-patient data from the 2023 fiscal year NBS program together with patient data for CPT II deficiency and very-long-chain acyl-CoA dehydrogenase deficiency derived from previously reported case series. Here, CPT2 is linked to long chain acyl-CoA dehydrogenase deficiency.